全文获取类型
收费全文 | 406篇 |
免费 | 18篇 |
专业分类
儿科学 | 1篇 |
妇产科学 | 1篇 |
基础医学 | 40篇 |
口腔科学 | 2篇 |
临床医学 | 16篇 |
内科学 | 243篇 |
皮肤病学 | 1篇 |
神经病学 | 8篇 |
特种医学 | 8篇 |
外科学 | 28篇 |
综合类 | 1篇 |
预防医学 | 7篇 |
药学 | 5篇 |
肿瘤学 | 63篇 |
出版年
2021年 | 4篇 |
2019年 | 3篇 |
2018年 | 6篇 |
2017年 | 3篇 |
2015年 | 4篇 |
2014年 | 6篇 |
2013年 | 9篇 |
2012年 | 5篇 |
2011年 | 8篇 |
2010年 | 6篇 |
2008年 | 15篇 |
2007年 | 17篇 |
2006年 | 23篇 |
2005年 | 12篇 |
2004年 | 15篇 |
2003年 | 16篇 |
2002年 | 19篇 |
2001年 | 15篇 |
2000年 | 6篇 |
1999年 | 6篇 |
1998年 | 5篇 |
1997年 | 4篇 |
1996年 | 8篇 |
1995年 | 5篇 |
1994年 | 5篇 |
1993年 | 3篇 |
1992年 | 6篇 |
1991年 | 8篇 |
1990年 | 6篇 |
1989年 | 8篇 |
1988年 | 6篇 |
1987年 | 10篇 |
1986年 | 14篇 |
1985年 | 8篇 |
1984年 | 14篇 |
1983年 | 7篇 |
1982年 | 7篇 |
1981年 | 4篇 |
1979年 | 6篇 |
1978年 | 2篇 |
1977年 | 4篇 |
1975年 | 5篇 |
1974年 | 10篇 |
1973年 | 13篇 |
1972年 | 18篇 |
1971年 | 8篇 |
1970年 | 10篇 |
1969年 | 4篇 |
1968年 | 4篇 |
1966年 | 2篇 |
排序方式: 共有424条查询结果,搜索用时 15 毫秒
101.
Nicolas Lamblin Thibaud Meurice Olivier Tricot Pascal de Groote Gilles Lemesle Christophe Bauters 《Journal of cardiac failure》2018,24(12):815-822
Background
We lack recent data on the incidence, correlates, and prognosis associated with heart failure (HF) development in patients with stable coronary artery disease (CAD). Here, we analyzed HF development in a contemporary population of outpatients with stable CAD.Methods and Results
Of 4184 unselected outpatients with stable CAD (ie, myocardial infarction [MI] and/or coronary revascularization >1 year earlier) included in the multicenter CORONOR registry, we identified 3871 patients with no history of hospitalization for HF at inclusion and followed 3785 (98%) of them for 5 years. During follow-up, 211 patients were hospitalized for HF (5-year cumulative incidence 5.7%) and 163 patients had incident MIs. Independent predictors of hospitalization for HF were older age, lower left ventricular ejection fraction (LVEF), atrial fibrillation, higher body mass index, diabetes mellitus, history of hypertension, angina at inclusion, and multivessel CAD. Most hospitalizations for HF (62.6%) occurred in patients with LVEF ≥50% at inclusion, and most (92.4%) were not preceded by an incident MI. Hospitalization for HF was a powerful predictor of mortality (adjusted hazard ratio 5.97, 95% confidence interval 4.55–7.83; P < .0001). After hospitalization for HF, mortality rates were similar in patients with LVEFs ≥50% and <50% at hospitalization.Conclusions
Outpatients with stable CAD were frequently hospitalized for HF, and HF was associated with high mortality. Most HF hospitalizations were associated with preserved LVEF at inclusion and were not preceded by an incident MI. 相似文献102.
Talamo G Cavallo F Zangari M Barlogie B Lee CK Pineda-Roman M Kiwan E Krishna S Tricot G 《Haematologica》2006,91(7):964-967
We report 24 cases of multiple myeloma (MM) with involvement of the gastrointestinal (GI) system. We found a strong association with high A lactate dehydrogenase levels, plasmablastic morphology, and A unfavorable karyotype. GI involvement at the time of initial diagnosis was much rarer than later in the course of the disease. The A median survival after diagnosis of GI involvement was 7 months. Among 13 patients treated with stem cell transplantation, the response rate was 92%, and median progression-free survival was 4 months. We conclude that MM involving the GI system is associated with adverse biological features and with short-lasting remissions, even after A high-dose chemotherapy. 相似文献
103.
Tumour lysis syndrome complicating high-dose treatment in patients with multiple myeloma 总被引:5,自引:0,他引:5
Athanasios B.-T. Fassas K. R. Desikan David Siegel Thomas A. Golper Nikhil C. Munshi Bart Barlogie & Guido Tricot 《British journal of haematology》1999,105(4):938-941
Tumour lysis syndrome (TLS), because of its low proliferative activity, is thought to only rarely complicate the treatment of patients with multiple myeloma. However, as more aggressive therapeutic approaches are increasingly used in the management of this disease, it is conceivable that clinicians will encounter this complication more frequently. A retrospective analysis of > 800 patients with multiple myeloma treated at the University of Arkansas identified nine patients who developed a marked tumour lysis syndrome following intermediate- or high-dose chemotherapy. Evaluation of disease characteristics revealed association with high tumour mass, high proliferative activity, increased lactic dehydrogenase levels, plasmablastic morphology, and unfavourable cytogenetic abnormalities. Recognition of multiple myeloma patients at high risk for the development of tumour lysis syndrome and prompt intervention are required especially in the presence of abnormal baseline renal function frequently complicating the clinical course of these patients. 相似文献
104.
The blood coagulation mechanism in multiple myeloma 总被引:8,自引:0,他引:8
Zangari M Saghafifar F Mehta P Barlogie B Fink L Tricot G 《Seminars in thrombosis and hemostasis》2003,29(3):275-282
Many cancers are associated with hypercoagulability, including multiple myeloma. At least four possible reasons for hypercoagulability have been described in myeloma patients: interference of immunoglobulins on fibrin structure, procoagulant autoantibody production, effects of inflammatory cytokines on endothelium, and acquired activated protein C (APC) resistance. Moreover, injury to endothelium, either by tumor cells or by chemotherapy, may predispose to thrombosis by causing upregulation of adhesion molecules, allowing adhesion of blood cellular elements (platelets, lymphocyte, neutrophils, and tumor cells, which secrete thrombogenic as well as angiogenic substances). In most cases, the pathogenesis of a thrombotic complication in myeloma patients remains unexplained. Administration of chemotherapy may play a larger role in the thrombotic process than a specific abnormality does because thrombotic complications become more prominent after the start of treatment. The recently reported evidence of a non-factor V Leiden APC resistance has increased our understanding of the pathophysiology of this hypercoagulable state. 相似文献
105.
Dhodapkar MV Weinstein R Tricot G Jagannath S Parfitt AM Manolagas SC Barlogie B 《Leukemia & lymphoma》1998,32(1-2):121-127
The net impact of malignancy and anti-tumor therapy on bone resorption in myeloma is poorly understood because conventional skeletal radiographs are relatively insensitive for the diagnosis and monitoring of bone disease. We performed determinations of bone mineral density (BMD) at the lumbar spine, femoral neck and radial diaphysis by dual energy X ray absorptiometry (DEXA) in 168 consecutive patients with myeloma seen at our institution. Follow up studies were performed in 41 of these patients. A detailed analysis of patient and disease characteristics was performed to identify the determinants of BMD. Compared to normal age and sex matched controls, mean (+/- SE) BMD was significantly decreased at the lumbar spine (Z score -0.4 +/- 0.10) and femoral neck (Z score -1.0 +/- 0.10), but was surprisingly above normal at the radial diaphysis (Z score +0.35 +/- 0.10), a cortical bone site devoid of hematopoietic marrow, suggesting a differential bone preserving effect at this site. Lack of correlation between the BMD findings and the presence or extent of radiographically evident osteolytic lesions suggested the presence of a systemic bone disease. On multivariate analysis, duration of disease >12 months (p = 0.003) and female sex (p = 0.01) were independently associated with a lower BMD at the femoral neck/lumbar spine. On follow up DEXA (n = 41), BMD increased at > or = 1 site in 9 of 20 patients receiving bisphosphonates and in only 2 of 21 patients not receiving such therapy (p = 0.02). Similarly a decline in BMD at > or = 1 site was seen in 9 of 21 patients not receiving bisphosphonates, irrespective of the disease response status. Interval pamidronate therapy (p = 0.0007) and a low serum beta-2-microglobulin (< 2.5 mg/l) (p = 0.04) were the two most significant variables associated with an increase in BMD on multivariate analysis. These data suggest that myeloma is associated with a systemic bone disease with progressive generalized cancellous bone loss and a bone preserving effect on the radial cortical bone. The early use of bisphosphonates may improve myeloma related bone disease. 相似文献
106.
Combined trisomy 1q and monosomy 7q due to translocation 1;7 in myelodysplastic syndromes 总被引:1,自引:0,他引:1
Two patients, possibly exposed to toxic agents, presented with a myelodysplastic syndrome (MDS) and a t(1;7) in bone marrow metaphases. This observation confirms the occurrence of this characteristic chromosome anomaly in MDS and its possible induction by environmental agents. It is hypothesized that this t(1;7) MDS may not be confined to a particular geographical area but that, in the past, it may have been overlooked in the absence of optimal banding, which is obviously necessary to identify the anomaly. 相似文献
107.
International uniform response criteria for multiple myeloma. 总被引:37,自引:0,他引:37
B G M Durie J-L Harousseau J S Miguel J Bladé B Barlogie K Anderson M Gertz M Dimopoulos J Westin P Sonneveld H Ludwig G Gahrton M Beksac J Crowley A Belch M Boccadaro M Cavo I Turesson D Joshua D Vesole R Kyle R Alexanian G Tricot M Attal G Merlini R Powles P Richardson K Shimizu P Tosi G Morgan S V Rajkumar 《Leukemia》2006,20(9):1467-1473
New uniform response criteria are required to adequately assess clinical outcomes in myeloma. The European Group for Blood and Bone Marrow Transplant/International Bone Marrow Transplant Registry criteria have been expanded, clarified and updated to provide a new comprehensive evaluation system. Categories for stringent complete response and very good partial response are added. The serum free light-chain assay is included to allow evaluation of patients with oligo-secretory disease. Inconsistencies in prior criteria are clarified making confirmation of response and disease progression easier to perform. Emphasis is placed upon time to event and duration of response as critical end points. The requirements necessary to use overall survival duration as the ultimate end point are discussed. It is anticipated that the International Response Criteria for multiple myeloma will be widely used in future clinical trials of myeloma. 相似文献
108.
109.
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3 总被引:3,自引:0,他引:3
Barlogie B Anaissie E van Rhee F Haessler J Hollmig K Pineda-Roman M Cottler-Fox M Mohiuddin A Alsayed Y Tricot G Bolejack V Zangari M Epstein J Petty N Steward D Jenkins B Gurley J Sullivan E Crowley J Shaughnessy JD 《British journal of haematology》2007,138(2):176-185
Total therapy 3 incorporated bortezomib into a melphalan-based tandem transplant regimen for 303 newly diagnosed patients with myeloma. Induction chemotherapy prior to and consolidation chemotherapy after transplants each consisted of two cycles of VTD-PACE (bortezomib, thalidomide, dexamethasone and 4-d continuous infusions of cis-platin, doxorubicin, cyclophosphamide, etoposide); 3-year maintenance comprised monthly cycles of VTD in the first and TD in the remaining years. The median age was 59 years (age >64 years, 28%). A minimum of 20 x 10(6) CD34 cells/kg was collected in 87% of patients; 83% completed both transplants, and only 5% suffered a treatment-related death. At 24 months, 83% had achieved near-complete remission, which was sustained in 88% at 2 years from its onset. With a median follow-up of 20 months, 2-year estimates of event-free and overall survival were 84% and 86% respectively. The 44 patients who experienced an event more often had a high-risk gene array profile, cytogenetic abnormalities and indicators of high lactate dehydrogenase, beta-2-microglobulin, creatinine and International Staging System stage. Toxicities of grade > 2 included thrombo-embolic events in 27% and peripheral neuropathy in 12%. Results of this phase-2 study demonstrated that bortezomib could be safely combined with multi-agent chemotherapy, effecting near-complete remission status and 2-year survival rates in more than 80% of patients. 相似文献
110.